title: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer.
abstract: OBJECTIVE
  To investigate the expression of markers that are correlated with the prognosis of colorectal cancer (CRC) patients.
  
  
  METHODS
  One hundred and fifty-six CRC patients were followed up for more than 3 years after radical surgery. Immunohistochemical (IHC) analysis was performed to detect the expression of 14 pathway-related markers (p53, APC, p21ras, E-cadherin, endothelin-B receptor, Shp2, ADCY-2, SPARCL1, neuroligin1, hsp27, mmp-9, MAPK, MSH2 and rho) in specimens from these patients. Bioinformatics analysis involving a Support Vector Machine (SVM) was used to determine the best prognostic model from combinations of these markers.
  
  
  RESULTS
  Seven markers (SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK) were significantly related to the prognosis and clinical pathological features of the CRC patients (P < 0.05). Prognostic models were established through SVM from combinations of these 7 markers and proved able to differentiate patients with dissimilar survival, especially in stage II/III patients. According to the best prognostic model, the p53/SPARCL1 model, patients having high p53 and low SPARCL1 expression had about 50% lower 3-year survival than others (P < 0.001).
  
  
  CONCLUSIONS
  SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are potential prognostic markers in CRC. A p53/SPARCL1 bioinformatics model may be used as a supplement to tumor-nodes-metastasis staging.
authors.affiliation: Department of Radiation Oncology, the Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, Zhejiang Province, China.
authors.forename: Shu-Jing
authors.initials: SJ
authors.lastname: Yu
authors.forename: Jie-Kai
authors.initials: JK
authors.lastname: Yu
authors.forename: Wei-Ting
authors.initials: WT
authors.lastname: Ge
authors.forename: Han-Guang
authors.initials: HG
authors.lastname: Hu
authors.forename: Ying
authors.initials: Y
authors.lastname: Yuan
authors.forename: Shu
authors.initials: S
authors.lastname: Zheng
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism; D015820:Cadherins / Q000378:metabolism*; D002135:Calcium-Binding Proteins / Q000378:metabolism*; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D006801:Humans; D053208:Kaplan-Meier Estimate; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D051718:MutS Homolog 2 Protein / Q000378:metabolism*; D009367:Neoplasm Staging; D011379:Prognosis; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11 / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; D002135:Calcium-Binding Proteins; D016326:Extracellular Matrix Proteins; C503126:SPARCL1 protein, human; D016159:Tumor Suppressor Protein p53; D020928:Mitogen-Activated Protein Kinases; D054592:Protein Tyrosine Phosphatase, Non-Receptor Type 11; C497172:MSH2 protein, human; D051718:MutS Homolog 2 Protein; D000262:Adenylyl Cyclases; C100622:adenylyl cyclase 2